Panelists:
Benjamin McLeod, PhD
Consultant
Cell and Gene Therapy Manufacturing
Qimin Quan, PhD
Chief Scientific Officer
NanoMosaic
Angad Garg, PhD
Senior Scientist
NanoMosaic
Sylvain Cecchini, PhD
Director of the AAV Large Scale Manufacturing
Facility Research Core
UMass Chan Medical School
Broadcast Date:
Time:
Adeno-associated virus (AAV) preparations remain highly heterogeneous through upstream and downstream bioprocessing phases. Characterizing empty, partial, full, overfilled capsids and encapsulated host cell DNAs is essential for proper dosing, patient safety, and manufacturing consistency. However, existing analytical methods used in gene therapy manufacturing processes operate in silos and lack harmonization, which can misrepresent the true therapeutic payload.
In this GEN webinar, our expert speakers will introduce NanoMosaic’s Tessie™, a fit-for-purpose platform for gene therapy applications that effectively combines protein and nucleic acid quantification in a single run. During the webinar, they will discuss how Tessie detects and characterizes AAV capsids as well as full, empty, partial, and internally deleted transgenes directly from crude extracts. You’ll also learn how to use the system to accurately quantify intact, full-length therapeutic transgenes throughout the manufacturing processes.
Key topics covered during the webinar include:
- How Tessie enables gene therapy researchers and manufacturers to standardize their process on a single platform
- How Tessie simplifies user training by using familiar workflows and harmonizing data points measured across upstream and downstream processes
- How the platform ensures high throughput throughout manufacturing
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
